Table 2.

Patients eligible for L-T₄/L-T₃ combination therapy at referral (mean/median and range)

	Total	Responders	Nonresponders	p value
At baseline	(n = 37)	(n = 24)	(n = 13)
Age, years		49 (22 – 72)	57 (36 – 79)	0.06
BMIa	28.3 (18.3 – 44.6)	28.4 (21.8 – 44.6)	28.1 (18.3 – 35.5)	0.91
TSHb, mIU/L	0.85 (0.08 – 4.2)	0.78 (0.08 – 4.20)	0.92 (0.1 – 3.06)	0.10
T4, nmol/L	109 (69 – 147)	108.1 (69 – 143)	109.8 (85 – 147)	0.78
T3b, nmol/L	1.20 (0.7 – 2.00)	1.2 (0.7 – 1.9)	1.2 (0.8 – 2.00)	0.94
Free T3 estimateb	1.12 (0.55 – 2.1)	1.16 (0.55 – 1.82)	1.08 (0.76 – 2.10)	0.63
After L-T4/L-T3 combination therapy	(n = 35)	(n = 24)	(n = 11)
TSHb, mIU/L	0.43 (0.01 – 4.02)	0.57 (0.01 – 4.02)	0.33 (0.02 – 2.42)	0.37
T4, nmol/L	95 (43 – 155)	90.0 (43 – 155)	106 (81 – 130)	0.04c
T3b, nmol/L	1.50 (0.8 – 2.4)	1.5 (0.8 – 2.4	1.3 (0.9 – 2.30)	0.50
Free T3 estimateb	1.38 (0.73 – 2.54)	1.41 (0.73 – 2.54)	1.33 (0.86 – 2.02)	0.56
Delta	(n = 35)	(n = 24)	(n = 11)
TSHb, mIU/L	0.30 (–3.94 to 3.79)	0.23 (–3.91 to 3.79)	0.47 (–1.07 to 2.18)	0.48
T4, nmol/L	–13.8 (–76 to 36)	–18 (–76 to 24)	–4.5 (–36 to 36)	0.54
T3, nmol/L	0.27 (–0.5 to 1.70)	0.28 (–0.5 to 1.70)	0.25 (–0.30 to 0.9)	0.85
Free T3 estimate	0.24 (–0.7 to 1.62)	0.24 (–0.77 to 1.62)	0.22 (–0.23 to 0.68)	0.89

^an = 16 responders, 7 nonresponders.

^bMedian when data is not Gaussian distributed.

^cSignificant result.